Fox Chase Cancer Center Names Roger Cohen Acting Chairman of Medical Oncology Department
PHILADELPHIA (Jan. 8, 2008) - Roger B. Cohen, MD, of Jenkintown, Pa., has become acting chairman of Fox Chase Cancer Center's department of medical oncology. He assumes the departmental responsibilities of outgoing chairman Louis M. Weiner, MD, who becomes director of Georgetown University's Lombardi Cancer Center effective January 1, 2008.
Cohen joined the medical oncology staff in 2001 as director of the phase I clinical trials program. Phase I trials, the first stage of clinical studies, test promising methods of cancer prevention, diagnosis and treatment to see if they are safe and effective.
"Dr. Cohen has distinguished himself as a highly effective clinical researcher, clinician and respected colleague throughout the Center," Fox Chase president and chief executive officer ., said in announcing Cohen's appointment as acting chair. "Dr. Cohen will work with the chairs of radiation oncology, surgical oncology, medicine, radiology and pathology in the coordination of clinical activities across the Center. I am enthusiastic and grateful to Dr. Cohen for taking on this important responsibility."
Board-certified in hematology and medical oncology, Cohen sees patients with head and neck, lung and genitourinary cancers. His research interests include clinical trial design and analysis and he has special expertise in monoclonal antibody therapy, which uses laboratory-crafted proteins to target specific cancer cells.
Before coming to Fox Chase, Cohen had been associate professor of hematology-oncology at the University of Virginia and director of its cancer center clinical trials office since 1994. Previously, he had been affiliated with the Food and Drug Administration's Center for Biologics Evaluation and Research as deputy director of the division of monoclonal antibodies in the office of therapeutics research and review.
Cohen earned his bachelor's degree magna cum laude from Harvard College in 1976 and was elected to Phi Beta Kappa. He received his MD in 1980 from Harvard Medical School and completed a residency in internal medicine and a fellowship in hematology at Mount Sinai Hospital in New York City.
Cohen held postdoctoral research fellowships in the laboratory of gene structure and expression at Memorial Sloan-Kettering Cancer Center and in the laboratory of molecular hematology at the National Heart, Lung and Blood Institute.
From 1989 to 1992, he was senior staff fellow in the division of cytokine biology at the FDA Center for Biologics Evaluation and Research. He also completed a medical oncology fellowship in the National Cancer Institute's clinical oncology program and was associate investigator for NCI's human immunodeficiency virus program.
The author of numerous research papers, Cohen is frequently invited to lecture on research and treatment topics at universities and cancer centers around the country and is a reviewer for several professional journals.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.